Related Experiment Videos

Intracerebral choriocarcinoma

W B Jones1, K M Wagner-Reiss, J L Lewis

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

Gynecologic Oncology
|August 1, 1990
PubMed

Insights

Gestational trophoblastic disease (GTD) brain metastases occurred in 9% of patients. Methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy showed limited success in preventing or treating brain metastases, with a 26.3% survival rate.

Area of Science:

  • Oncology
  • Neurology
  • Gynecology

Background:

  • Gestational trophoblastic disease (GTD) can metastasize to the brain.
  • Brain metastases represent a significant challenge in GTD management.

Purpose of the Study:

  • To review outcomes of patients with GTD metastatic to the brain.
  • To evaluate the role of methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy in these patients.

Main Methods:

  • Retrospective review of 19 patients with GTD metastatic to the brain treated between 1967 and 1987.
  • Analysis of chemotherapy regimens, including MAC, and whole-brain radiotherapy.

Main Results:

  • Brain metastases occurred in 9.0% of GTD patients.
  • 26.3% (5/19) of patients with brain metastases survived long-term.
  • MAC chemotherapy did not consistently prevent brain metastases and was less effective in resistant cases.

Conclusions:

  • Whole-brain radiotherapy was standard treatment.
  • The efficacy of MAC chemotherapy in preventing or treating GTD brain metastases appears limited.
  • Further research into optimal treatment strategies for GTD brain metastases is warranted.

Related Concept Videos